71 results
Page 2 of 4
8-K
EX-10.7
ltkdpv
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
nh05fyno4g et00tg
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
8-K
EX-99.2
hux72vje
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
z0cgud sro
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
bwq2l4 rry4ltzz91
13 Jan 20
Other Events
8:06am
8-K
2k8qho
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.1
2kz2 blj13lwxh0
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
02gp84miyv
2 Dec 19
Other Events
5:18pm
8-K
EX-99.2
u7q5bc912dfyp
20 Nov 19
Other Events
7:05am
8-K
EX-99.1
c56hvpv9p4d ns454l
3 Oct 19
Other Events
7:15am
8-K
EX-99.2
7i7b3zyk
27 Sep 19
Other Events
10:15am
8-K
EX-99.1
tbji9z2ml4
27 Sep 19
Other Events
10:15am
S-8
EX-99.1
jutd z079kvdp
20 Sep 19
Registration of securities for employees
4:09pm
8-K
EX-99.1
qo6 1qz7w
12 Aug 19
Other Events
7:05am
8-K
EX-99.1
xlsum0onr5odxbyt5uas
8 Aug 19
Aravive Announces Executive Management Transition Plan
5:06pm
8-K
EX-99.1
anr9tolb3fzyz2ua4ig
31 Jul 19
Aravive Reports Preliminary Results ofAVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial
7:15am